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ABCG2 is a key human ATP-binding cassette (ABC) transporter mediating cancer cell
chemoresistance. In the case of ABCC1, another multidrug transporter, earlier ﬁndings
documented that certain modulators greatly increase ABCC1-mediated glutathione (GSH)
efﬂux and, upon depletion of intracellular GSH, induce “collateral sensitivity” leading to the
apoptosis of multidrug resistant cells. Recently, it has been suggested that ABCG2 may
mediate an active GSH transport. In order to explore if ABCG2-overexpressing cells may
be similarly targeted, we ﬁrst looked for the effects of ABCG2 expression on cellular GSH
levels, and for an ABCG2-dependent GSH transport in HEK293 and MCF7 cells.We found
that, while ABCG2 overexpression altered intracellular GSH levels in these transfected
or drug-selected cells, ABCG2 inhibitors or transport modulators did not inﬂuence GSH
efﬂux. We then performed direct measurements of drug-stimulated ATPase activity and
3H-GSH transport in inside-out membrane vesicles of human ABC transporter-
overexpressing Sf9 insect cells. Our results indicate that ABCG2-ATPase is not modulated
by GSH and, in contrast to ABCC1, ABCG2 does not catalyze any signiﬁcant GSH transport.
Our data suggest no direct interaction between the ABCG2 transporter and GSH, although
a long-term modulation of cellular GSH by ABCG2 cannot be excluded.
Keywords: breast cancer resistance protein ABCG2, collateral sensitivity, glutathione efflux, intracellular glu-
tathione depletion, multidrug resistance protein ABCC1, selective apoptosis, modulators
INTRODUCTION
The development of multidrug resistance (MDR) constitutes a
major issue in cancer treatment. Overexpression of the three
human ATP-binding cassette (ABC) transporters, ABCB1 (P-
glycoprotein/P-gp; Juliano and Ling, 1976), ABCC1 (multidrug
resistance protein 1/MRP1; Cole et al., 1992), and ABCG2 (breast
cancer resistance protein, BCRP;Allikmets et al., 1998; Doyle et al.,
1998; Miyake et al., 1999) has been proposed as one of the main
causes of the MDR phenotype in resistant cancer cells. These pro-
teins use ATP hydrolysis as energy source to catalyze the efﬂux of
multiple structurally and functionally diverse chemotherapeutics
from cancer cells.
Research has mainly focused on inhibitors development, in
order to block this efﬂux mechanism and then restore chemother-
apeutics efﬁcacy. Unfortunately, scientists had to face clinical
failures of third-generation ABCB1 inhibitors optimized in vitro,
such as Zosuquidar (Cripe et al., 2010) or valspodar (Kolitz et al.,
2010). In addition to improving clinical trials conducted with
efﬂux inhibitors (Robey et al., 2010), alternative strategies to
Abbreviations: ABC, ATP-binding cassette; BCRP (ABCG2), breast cancer resis-
tance protein; CS, collateral sensitivity; 2′,5′-DHC, 2′,5′-dihydroxychalcone; DNP-
SG, S-(2,4-dinitrophenyl)glutathione; GSH, reduced glutathione; MDR, multidrug
resistance; MRP1 (ABCC1), multidrug resistance protein 1; P-gp (ABCB1),
P-glycoprotein
overcome the MDR phenotype need to be explored. Recently, a
new strategy, so called collateral sensitivity (CS), characterized by
hypersensitivity to small molecules triggering a preferential cyto-
toxicity, has been studied (Szakacs et al., 2006; Hall et al., 2009),
and four differentmechanisms have been hypothesized to underlie
the hypersensitivity of ABCB1- andABCC1-overexpressing cancer
cells. CS agents may (i) produce reactive oxygen species by deplet-
ing intracellular ATP; (ii) exploit energetic sensitivities caused by
ATP depletion; (iii) induce the extrusion of vital endogenous sub-
strates; or (iv) perturb the plasma membrane (Pluchino et al.,
2012).
A screening study identiﬁed two compounds as potential
ABCG2-relatedCS agents inHEK293 transfected cells, oneof them
(NSC103054) directly interacting with the transporter (Deeken
et al., 2009), and very recently an ABCG2 inhibitor (NP-1250)
was reported to induce CS in mitoxantrone-selected MCF7 cancer
cells (Ito et al., 2013). Although a mechanism based on extra-
cellular vesicles photodestruction have been shown for another
ABCG2-dependent CS (Goler-Baron and Assaraf, 2012), no direct
mechanisms have yet been demonstrated; however, these differ-
ent studies indicate that CS agents, speciﬁc for ABCG2, could be
developed.
Reduced glutathione (GSH, γ-glutamyl-cysteinyl-glycine) is a
tripeptide ubiquitously expressed in cells and involved in many
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signaling pathways. It has been shown thatABCC1-overexpressing
cells were hypersensitive to verapamil through a sharp GSH deple-
tiondue to anABCC1-mediated efﬂux (Trompier et al.,2004). This
phenomenon was further investigated in order to target resistant
cancer cells in the frame of a new strategy to overcome the MDR
phenotype in cancer (Barattin et al., 2010; Genoux-Bastide et al.,
2011). ABCC1 is also known to transport oxidized glutathione
disulﬁde (GSSG) which is however present in low amounts
(Keppler et al., 1997). Based on our experience with ABCC1-
speciﬁc CS and on recent reports in which ABCG2 was proposed
as a new GSH transporter (Brechbuhl et al., 2009, 2010) we aimed
at developing new ABCG2-speciﬁc modulators able to induce
ABCG2-mediated GSH extrusion in order to induce a drastic
intracellular GSH depletion leading to cell death.
In this study, we focused on searching inducers of ABCG2-
dependent depletion of intracellular GSH among known death
inducers of ABCC1-overexpressing cells, such as verapamil and
xanthones (Genoux-Bastide et al., 2011), or known ABCG2
inhibitors (Ahmed-Belkacem et al., 2005; Valdameri et al., 2012).
To ascertain the direct role of ABCG2 in GSH efﬂux, we measured
direct transport of radioactive GSH in membrane vesicles.
MATERIALS AND METHODS
COMPOUNDS
Verapamil, Ko143, apigenin, ATP, chrysin, ditiothreitol
(DTT), galangin, 5,5′-dithiobis(2-nitrobenzoic acid; DTNB),
β-nicotinamide adenine dinucleotide 2′-phosphate reduced tetra-
sodium salt hydrate (NADPH), quercetin, glutathione (GSH),
glutathione reductase, and bicinchoninic acid (BCA) were pur-
chased from Sigma Aldrich (Saint-Quentin Fallavier, France).
Acivicin was purchased from CliniSciences (Montrouge, France).
3H-methotrexate and 3H-GSH were purchased from Moravek
Biochemicals and PerkinElmer, respectively. All other tested com-
pounds were kindly provided by Prof. Ahcène Boumendjel (UJF
Grenoble, France) and prepared as previously described (Genoux-
Bastide et al., 2011; Valdameri et al., 2012). Tested compounds
were dissolved in DMSO and stored at −20◦C; they were warmed
to 25◦C and diluted in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) just before use (0.5% DMSO ﬁnal concentration).
CELL CULTURE
The cell lines were kindly provided by Drs Susan Bates and Robert
Robey, NCI, Bethesda, MD, USA. The selected human breast can-
cer cell line (MCF7-MX100) and the human ﬁbroblast HEK293
cell line transfected with either ABCG2 (HEK-ABCG2) or the
empty vector (HEK-pcDNA3.1) were prepared as respectively
reported (Honjo et al., 2001; Robey et al., 2003). The HEK293 and
MCF7 cells were maintained in DMEM (high glucose, PAA) and
in Roswell Park Memorial Institute medium (RPMI-1640, PAA)
respectively, supplemented with 10% fetal bovine serum (FBS,
PAA), 1% penicillin/streptomycin (PAA) and with 0.75 mg/ml
G418 (for HEK-pcDNA3.1 and HEK-ABCG2 cells) or 100 nM
mitoxantrone (for MCF7-MX100 cells). Cells were cultured at
37◦C, 5% CO2 in a humid atmosphere. Sf9 insect cells were cul-
tured at 27◦C inTNM-FH insectmedium supplementedwith 10%
fetal calf serum (FCS) and penicillin (100 U/ml)–streptomycin
(100 μg/ml; Sigma Aldrich, Hungary).
INTRACELLULAR GLUTATHIONE ASSAY
HEK293 and MCF7 cells were seeded in 96-well plates at respec-
tive densities of 1 × 104 and 2 × 104 cells/well. After 24 h
in culture, cells were exposed to the different compounds dur-
ing 6 or 24 h under normal culture conditions. They were then
washed with 200 μl PBS 1X (PAA), stirred during 1 h at 4◦C
with 100 μl of 10 mM HCl and freezed at −20◦C overnight, to
be lysed. The intracellular total glutathione (reduced GSH and
oxidized GSSG) was measured using the method described by
Tietze (1969) as modiﬁed by Anderson (1985). About 70 μl of
the lysate were used to measure intracellular total glutathione and
20 μl for protein quantitation, both being performed in 96-well
plates. Total glutathione was assessed by adding 100 μl of a reac-
tion buffer containing 266 μM NADPH,GSH reductase at 10 U/ml
and 555 μM DTNB, and the absorbance was read at 412 nm in
a microplate reader (PowerWave 340, Biotek) every 30 s during
2 min. The slope for each sample and glutathione standard range
was determined to quantify sample glutathione. Protein quan-
titation was performed using the BCA assay. The results were
expressed in nmol glutathione/mg protein and intracellular total
glutathione percentages were calculated using the 0 μM samples
as 100%.
EXTRACELLULAR GLUTATHIONE ASSAY
HEK293 cells were seeded in 24-well plates at a density of 1.5× 105
cells/well. After 24 h in culture, cells were co-treated with the com-
pound and 0.5 mM acivicin (to block GSH degradation out of
the cells) during the 24-h incubation time. Supernatants were col-
lected and cells were washed with 200 μl PBS 1× and treated
as for intracellular total glutathione measurement. About 70 μl
of the supernatant were used to assess total extracellular glu-
tathione, and protein titration was performed with cell lysate,
by the same method as described for intracellular glutathione
measurement.
CELL PROLIFERATION AS DETERMINED BY MTT ASSAY
The MTT colorimetric assay, as previously described (Mosmann,
1983), was used to assess the sensitivity of cells to compounds
toxicity. HEK293 cells were seeded in 96-well plates at a density of
1 × 104 cells/well. After 24 h under normal culture conditions,
cells were treated with compounds at increasing concentra-
tions. After 72-h incubation under normal culture conditions a
3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazoliumBromide
(MTT) solution was added (0.5 mg/ml ﬁnal concentration) in
wells, and cells were incubated for 4 h at 37◦C. Thereafter, super-
natants were carefully withdrawn and 100 μl/well of the buffer
ethanol/DMSO (50/50, v/v) were added to solubilize the reduced
formazan dye under stirring. Absorbance at 570 and 690 nm
were determined by using a microplate reader (PowerWave 340,
Biotek). Results were expressed as the difference between OD570
and OD690; cell survival percentage was calculated using 0 μM
sample OD as 100%.
MEMBRANE PREPARATION
For obtaining membrane vesicles insect cells were infected with
recombinant baculoviruses containing the cDNA of wtABCG2 or
ABCG2-K86M (Ozvegy-Laczka et al., 2005) or of ABCC1 (Bakos
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et al., 1996). Membranepreparation and cholesterol enrichment of
ABCG2-containing membranes was then performed as described
earlier (Ozvegy et al., 2001; Telbisz et al., 2007).
ATPase ACTIVITY ASSAY
The ATP hydrolytic activity of ABCG2 has been determined as
described in Ozvegy et al. (2001) and Telbisz et al. (2007). When
the effect of GSH was investigated a minor modiﬁcation in the
assay buffer was introduced. About 10 mM DTT was used instead
of 2 mM to prevent the oxidation of GSH.
3H-METHOTREXATE AND 3H-GSH TRANSPORT ASSAY
Sf9 membrane vesicles containing 90 μg protein were incu-
bated in the presence or absence of 4 mM MgATP (or 4 mM
MgATP + 1 μM Ko143 or 4 μM MK571) in a buffer contain-
ing 40 mM 3-(N-morpholino) propanesulfonic acid–Tris (pH
7.0), 56 mM KCl, 6 mM MgCl2, and 10 mM DTT, in a ﬁnal
volume of 140 μl, at 37◦C for 5–10 min as indicated on the
ﬁgure legends. The measurement was started by the addition of
50 μM [3H]methotrexate (Moravek Biochemicals) or 0.1–1 mM
3H-GSHand carried out as described earlier (Ozvegy-Laczka et al.,
2005).
STATISTICAL ANALYSIS
Statistic t-test analyses were performed using the SigmaPlot 12
software with *p < 0.05, **p < 0.01, ***p < 0.001.
RESULTS
INTRACELLULAR GLUTATHIONE CONCENTRATION IN
ABCG2-OVEREXPRESSING CELLS
In order to determine the inﬂuence of ABCG2 on cellular glu-
tathione levels, we used two different cell lines overexpressing this
transporter. The high level of ABCG2 expression and functionality,
through ability to transport a number of substrate drugs, were pre-
viously described, in both transfected HEK-ABCG2 cells (Robey
et al., 2003) and drug-selected MCF7-MX100 cancer cells (Honjo
et al., 2001). Moreover, we performed western blot analyses which
revealed that all cell lines did not express the ABCC1 protein (data
not shown). The intracellular concentration of total glutathione
(free GSH + oxidized GSSG) appeared to be signiﬁcantly mod-
ulated by the presence of overexpressed ABCG2 (Figure 1). The
glutathione level was lower in ABCG2-transfected HEK293 cells
by comparison to the same cells transfected by the pcDNA3.1
empty vector (100 ± 8 versus 130 ± 11 nmol glutathione/mg pro-
tein). Interestingly, in drug-selected MCF7 cancer cells, which also
overexpress ABCG2, the intracellular glutathione content was sig-
niﬁcantly higher than in the parental MCF7 cells (154 ± 7 versus
125 ± 10 nmol glutathione/mg protein). These data may indicate
a long-term modulation of glutathione levels in various ABCG2-
overexpressing cell types. Since total glutathione is known to be
essentially constituted of free GSH and low amounts of oxidized
GSSG, we measured both components separately in the differ-
ent cell lines, upon incubation with 2-vinylpiridine behaving as
a thiol scavenger. In all cases, the remaining oxidized GSSG was
too low to be detected (not shown here), indicating no evidence
of any change in the ratio between reduced and oxidized forms of
glutathione.
FIGURE 1 | Basal total intracellular glutathione levels in HEK293 or
MCF7 cells.The values of either ABCG2-overexpressing cells (white bars)
or control cells (black bars) represent means ± SD corresponding to at least
three independent experiments performed in triplicates. The differences
observed between both cell line pairs were signiﬁcantly different. t -test
analysis: ***p < 0.001.
INABILITY OF MODULATORS TO STIMULATE AN ACTIVE
ABCG2-MEDIATED GLUTATHIONE EFFLUX
Since the 2′,5′-DHC chalcone was reported to stimulate ABCG2-
dependent GSH efﬂux (Brechbuhl et al., 2010), the effects pro-
duced by addition of 2′,5′-DHC at increasing concentrations
(up to 40 μM) were analyzed here on the intracellular glu-
tathione levels of both transfected and drug-selected cells. A
weak concentration-dependent decrease appeared in ABCG2-
transfected cells after 6-h incubation with 2′,5′-DHC (Figure 2A),
but not after 24-h incubation where an increase in intracellular
glutathione content was observed in both cell lines (Figure 2B). By
contrast, in drug-selected MCF7 cells, no decrease in glutathione
content appeared after 6-h incubation (Figure 2C); a signiﬁcant
difference in glutathione level was observed after 24-h incubation,
which was however essentially due to a higher increase in con-
trol cells than in ABCG2-overexpressing cells (Figure 2D). The
extracellular glutathione content increased after 24-h incubation
of ABCG2-transfected cells with increasing 2′,5′-DHC concentra-
tions (around 40% at 10 μM), but the increase was at least as high
in control cells indicating that it was not dependent on ABCG2
(Figure 2E).
We then studied the effects of verapamil which is known to
strongly stimulate GSH efﬂux in ABCC1-overexpressing cells,
leading to a fast and massive intracellular glutathione deple-
tion able to trigger apoptosis (Trompier et al., 2004; Perrotton
et al., 2007). A signiﬁcant decrease of intracellular glutathione
was indeed observed in ABCG2-transfected cells with increas-
ing verapamil concentrations, up to 40 μM, which was 25–30%
higher than in control HEK293 cells (Figure 3A). However, no
decrease in glutathione content was observed under the same
conditions with the ABCG2-overexpressing drug-selected cells,
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FIGURE 2 | Effects of 2′,5′-DHC increasing concentrations on total
intracellular and extracellular glutathione levels. 2′,5′-DHC did not
induce intracellular GSH depletion in ABCG2 cells (white circles) by
comparison to control cells (black circles) in either HEK293 transfected
cells during 6 (A) or 24 h (B), or MCF7 cancer cells during 6 (C) or
24 h (D). Moreover, there was no net ABCG2-dependent increase in
extracellular GSH (E) induced by 2′,5′-DHC when comparing HEK-ABCG2
(white bars) and HEK-pcDNA3.1 (black bars) cells after 24-h incubation.
The values represent means ± SD corresponding to at least two inde-
pendent experiments performed in triplicates. Only the differences obser-
ved in (D), between MCF7 and MCF7-MX100 cell lines at 24 h, were
signiﬁcant. t -test analysis: *p < 0.05, **p < 0.01, and ***p < 0.001.
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FIGURE 3 | Effects of verapamil on intracellular glutathione depletion
and cells survival. Verapamil induced a signiﬁcant intracellular GSH
depletion in HEK293 transfected cells during 6-h incubation (A), but not in
the MCF7 selected cells (B) when comparing ABCG2-overexpressing cells
(white circles) to control cells (black circles). This weak effect was not
inhibited by Ko143 (C), the difference in intracellular glutathione remaining
unchanged. It was not either correlated to any ABCG2-speciﬁc collateral
sensitivity in MTT cell survival assays (D) with ABCG2-overexpressing cells
(white circles) and control cells (black circles). The values represent
means ± SD corresponding to at least two independent experiments
performed in triplicates. t -test analysis: *p < 0.05, **p < 0.01, and
***p < 0.001.
which behaved similarly to control MCF7 cells (Figure 3B). The
ABCG2-related decrease of intracellular glutathione was therefore
further characterized in the presence of Ko143, a potent and spe-
ciﬁc inhibitor of ABCG2 transport activity. Figure 3C shows no
signiﬁcant alteration by comparison to Figure 3A, therefore indi-
cating that such a decrease in intracellular glutathione was not
dependent on ABCG2 activity. This was further conﬁrmed by the
absence of any CS toward verapamil cytotoxicity, as determined
by MTT assays, since the ABCG2-transfected cells were not more
sensitive than the control cells (Figure 3D).
Finally, two other series of compounds were investigated for
their ability to modify the intracellular glutathione level. The
ﬁrst series included xanthones (X8, 9, 10, 18, 22, 23) known to
induce, similarly as verapamil, a strong depletion in intracellu-
lar glutathione in ABCC1-overexpressing cells (Genoux-Bastide
et al., 2011), and the second series contained chalcones (C27, 37,
38, 40; Valdameri et al., 2012) and 6-prenylchrysin (6-Pc; Ahmed-
Belkacem et al., 2005) known asABCG2 inhibitors. Figure 4 shows
that some xanthones induced a signiﬁcant decrease in intracellular
glutathione, up to around 30% for X8 and X9 and 20% for X23,
similarly to the effect observed with verapamil in Figure 3A.
By contrast, the ABCG2 inhibitory chalcones, except for C27,
and 6-prenylchrysin did not induce any decrease of intracellular
glutathione in ABCG2-transfected cells.
NO DETECTABLE INTERACTION BETWEEN GSH AND ABCG2 IN EITHER
ATPase OR TRANSPORT ASSAY
We previously demonstrated that the baculovirus-insect cell het-
erologous expression system is a useful tool for the detection of
interactions between a given test compound and ABCG2 (Szakács
et al., 2008). Brieﬂy, compounds modifying the ATP hydrolytic
activity of ABCG2 interact with the transporter, and can be either
transported substrates or inhibitors of the protein. In order to
deﬁne whether GSH is able to interact withABCG2, we have tested
its effect in the ATPase assay using cholesterol-loaded Sf9 vesicles
ensuring higher ABCG2 activity. We found that the ATPase activ-
ity of ABCG2 was not affected by GSH addition up to 10 mM, by
contrast to a transported substrate such as 1 μM quercetin which
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FIGURE 4 | Effects of other modulators on ABGC2-specific intracellular
glutathione depletion. Screening of Xanthones (Genoux-Bastide et al.,
2011), Chalcones (Valdameri et al., 2012), and 6-Prenylchrysin
(Ahmed-Belkacem et al., 2005) reveal a signiﬁcant ABCG2-dependent
intracellular glutathione depletion in 6-h incubation for some compounds,
as indicated. The values represent means ± SD corresponding to at least
two independent experiments performed in triplicates. t -test analysis:
*p < 0.05, **p < 0.01.
stimulated twofold the basal ATPase activity, and the ABCG2-
speciﬁc inhibitor Ko143 which fully inhibited (Figures 5A,B).
GSH did not alter the quercetin-stimulated ATPase activity either.
Moreover, no effect was produced by the glutathione-conjugate
S-(2,4-dinitrophenyl)glutathione (DNP-SG; Figure 5B) known to
be actively transported by ABCC1 (Leier et al., 1994).
As the ATPase assay did not give any proof of interaction
between GSH and ABCG2, we investigated the ability of GSH to
modify the transport of 3H-methotrexate. As shown in Figure 6,
the ABCG2-mediated transport of tritiated methotrexate was not
signiﬁcantly inhibited by GSH addition, up to a 10 mM concentra-
tion, by differencewith 1μMKo143 leading to the lowbackground
level observed with inactive mutant ABCG2. This contrasts with
the reported prevention by 10 μM methotrexate against the
increased extracellular GSH level observed in transformed yeast
expressing human ABCG2 (Brechbuhl et al., 2010).
INABILITY OF ABCG2 TO CATALYZE AN ACTIVE TRANSPORT OF GSH
Finally, wemeasured the direct transport of 3H-GSH intoABCG2-
containing membrane vesicles. We found that, in contrast to
ABCC1 serving as a positive control, nodirect,ATP-dependent and
speciﬁc inhibitor-sensitive, transport of tritiated GSH by ABCG2
could be detected in insect-cell membrane vesicles (Figure 7).
Any ABCG2-mediated GSH transport could not be either deter-
mined at other 3H-GSH concentrations (0.1 or 1 mM, data not
shown).
DISCUSSION
The key results of this paper strongly suggest that human ABCG2
is unable to transport GSH. This has been demonstrated by
direct measurement of ATP-dependent tritiated GSH uptake in
inverted vesicles of insect-cell membranes overexpressing human
ABCG2. In contrast, human ABCC1 catalyzed a high level of ATP-
dependent and MK571-sensitive GSH transport under the same
conditions. Therewas a low level of GSHaccumulation in the pres-
ence of ABCG2 observed without ATP, which was also observed in
the presence of the selective ABCG2 inhibitor Ko143 (Allen et al.,
2002), or when the catalytically inactive K86M ABCG2 mutant
was expressed. Thus, this background GSH binding could not be
attributed to any ABCG2-mediated active transport.
This result is fully consistent with the lack of effect of GSH, even
at high concentrations, on both basal and quercetin-stimulated
ABCG2-ATPase activity of the insect cell membrane vesicles.
Indeed, transported substrates such as prazosin, quercetin, or
nilotinib (Telbisz et al., 2012) strongly stimulate the basal ATPase
activity, then enhancing “coupled” ATPase activity. Our present
results also show the lack of any effect by DNP-SG on the ABCG2
transporter, suggesting that glutathione conjugates are not trans-
ported by ABCG2. This is in contrast to various compounds
conjugated with either sulfate (Suzuki et al., 2003) or glucuronate
(Chen et al., 2003), whereas DNP-SG is actively transported by
ABCC1 (Leier et al., 1994). The lack of ABCG2-mediated GSH
transport is also consistentwith the lack of any antagonismbyGSH
addition against ABCG2-mediated tritiated-methotrexate trans-
port in inverted vesicles. These results, however disagree with the
methotrexate-induced inhibition of GSH efﬂux reported in trans-
formed yeast cells, expressing human ABCG2 (Brechbuhl et al.,
2010).
Our results from experiments using membrane vesicles are
quite consistent with those obtained with either transfected
or drug-selected ABCG2-overexpressing cells where we did not
observe any sharp and rapid decrease of intracellular GSH stimu-
lable by modulators (such as 2′,5′-DHC, verapamil, or xanthones),
or alterable by ABCG2 inactivation (such as using the potent
Ko143 inhibitor). In addition, there was no inverse correla-
tion between the observed decrease of intracellular GSH and
increase of extracellular GSH, as also noticed in other drug-
selected cancer cells overexpressing ABCG2 (Brechbuhl et al.,
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FIGURE 5 | Effects of GSH and DNP-SG on the ATP hydrolytic
activity of ABCG2. Sodium orthovanadate-dependent ATP cleavage by
wtABCG2 in 2 mM cholesterol-loaded Sf9 membrane vesicles was
determined in the presence of increasing concentrations of GSH
(A) both in the absence (“basal”) and in the presence of a known
transported substrate (1 μM quercetin, “quercetin-stimulated”) without
producing any signiﬁcant effect. It was also assayed with increasing
concentrations of DNP-SG or quercetin or with 1 μM Ko143 (B). Data
points represent the average ± SD values of two independent
measurements.
2010). This contrasts with the strong effects clearly observed with
ABCC1-overexpressing cells (Trompier et al., 2004; Perrotton et al.,
2007; Barattin et al., 2010; Genoux-Bastide et al., 2011).
Nevertheless, the intracellular total glutathione concentration
appeared to be modulated by overexpressed ABCG2 since, for
unknown reasons possibly resulting from different signaling path-
ways, glutathione was lower in HEK293 transfected cells and
higher in the drug-selected MCF7 cancer cells by comparison to
their respective control cells. In addition, a signiﬁcant decrease
of intracellular glutathione was actually observed, either in some
cases with 2′,5′-DHC, as previously reported (Brechbuhl et al.,
2010), or with known ABCC1 modulators such as verapamil and
xanthones. Such a decrease of intracellular glutathione however
displayed special characteristics, such as being slow, requiring at
least 6–24 h incubation, and not depending on ABCG2 activity
since it was not altered by Ko143 inhibition. These results are
more likely compatible with the induction of associated signaling
pathways, leading to changes in intracellular GSH, than with a
direct GSH transport.
ABCG2 is known to be regulated by a number of signal-
ing pathways including NF-KB (Shen et al., 2010), RAR/RXR
(Hessel and Lampen, 2010), hedgehog (Singh et al., 2011),
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FIGURE 6 | Effect of GSH on the transport of methotrexate by ABCG2.
ATP-dependent transport of 3H-methotrexate in 2 mM cholesterol-loaded
insect-cell membranes expressing ABCG2 (either wild-type or the inactive
K86M mutant) was measured for 10 min at 37◦C. Transport was
determined in the absence or presence of an ABCG2-speciﬁc inhibitor
(1 μM Ko143) or 1–10 mM GSH. Bars represent the average ± SD values of
at least two measurements. t -test analysis: ***p < 0.001.
FIGURE 7 | Investigation of the transport of 3H-GSH into
wtABCG2-containing insect vesicles. Uptake of 500 μM 3H-GSH was
measured in Sf9 vesicles expressing ABCC1, wtABCG2, or inactive
ABCG2, for 5 min at 37◦C. ATP-dependent transport with or without the
ABCC1- or ABCG2-speciﬁc inhibitor, 4 μM MK-571 or 1 μM Ko143
respectively, is shown. Bars represent the average of three independent
measurements ± SD values. t -test analysis: ***p < 0.001.
P13K/AKT (Nakanishi and Ross, 2012), JNK1/c-jun (Zhu et al.,
2012), HER2 and EGFR/HER1 (Gilani et al., 2012), and ERK1/2
(de Boussac et al., 2012). Some signaling pathways, such as notch
(Battacharya et al., 2007), CXCL12-CXCR4 (Katoh and Katoh,
2010), Oct4-TCL1-AKT (Wang et al., 2010), PTEN/P13K/Akt (Li
et al., 2011), β-catenin/Tcf (Usongo and Farookhi, 2012), AhR
(Dubrovska et al., 2012), and HIF-2α with TGF-β/Smad2 (Cui
et al., 2013) are related to the ABCG2 status as a marker of stem
cells or stem-like cancer cells. Nrf2, a critical transcription fac-
tor that regulates antioxidants, detoxiﬁcation enzymes, and drug
efﬂux proteins in response to oxidative stress (Hong et al., 2010;
Singh et al., 2010; Chen et al., 2012; Zhang et al., 2012; Ishikawa
et al., 2013; Shelton and Jaiswal, 2013),may provide a link between
cellular GSH homeostasis and ABCG2 expression. Whatever the
mechanism(s) involved, changes in intracellularGSHare evidently
too slow and too low to induce a sufﬁcient cellular GSH depletion
susceptible to trigger CS-induced cell apoptosis, as observed for
ABCC1. It is still an important question if, and how, an ABCG2-
dependent CS can effectively be produced. Indeed, the few known
examples report very low selectivity ratio values, limited to 2.5–
3 (Deeken et al., 2009), by comparison with the values, at least
one order of magnitude higher, reported for both ABCB1- (Lud-
wig et al., 2006; Hall et al., 2009; Türk et al., 2009; Pluchino et al.,
2012) and ABCC1- (Trompier et al., 2004; Barattin et al., 2010;
Genoux-Bastide et al., 2011) overexpressing cells. Such a differ-
ence may be at least partly related to the complex involvement
of ABCG2 in many signaling pathways. Further identiﬁcation and
characterizationof mechanismsdirectly connectingABCG2 toCS-
associated apoptosis and signaling are mandatory for establishing
a new therapeutic strategy, selectively targeting and eliminating
resistant cancer cells.
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